Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Crosses Above 50-Day Moving Average – Time to Sell?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) shares crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $8.41 and traded as high as $8.50. Corbus Pharmaceuticals shares last traded at $8.18, with a volume of 120,634 shares traded.

Analysts Set New Price Targets

CRBP has been the subject of several research reports. Oppenheimer upped their price objective on shares of Corbus Pharmaceuticals from $53.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, March 10th. Jefferies Financial Group raised shares of Corbus Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, February 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Corbus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.71.

Corbus Pharmaceuticals Price Performance

The company has a market capitalization of $145.11 million, a PE ratio of -1.37 and a beta of 2.84. The business’s 50 day simple moving average is $8.41 and its 200 day simple moving average is $10.49.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings results on Monday, March 9th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, beating the consensus estimate of ($1.78) by $0.53. As a group, analysts anticipate that Corbus Pharmaceuticals Holdings, Inc. will post -4.23 EPS for the current year.

Insider Buying and Selling at Corbus Pharmaceuticals

In other news, insider Dominic Smethurst sold 3,285 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $8.09, for a total transaction of $26,575.65. Following the completion of the transaction, the insider directly owned 95,887 shares in the company, valued at approximately $775,725.83. This represents a 3.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Aberdeen Group plc increased its position in shares of Corbus Pharmaceuticals by 602.2% during the fourth quarter. Aberdeen Group plc now owns 1,321,750 shares of the biopharmaceutical company’s stock valued at $10,759,000 after acquiring an additional 1,133,519 shares during the last quarter. Orbimed Advisors LLC lifted its holdings in shares of Corbus Pharmaceuticals by 36.3% in the 4th quarter. Orbimed Advisors LLC now owns 1,597,287 shares of the biopharmaceutical company’s stock worth $13,002,000 after acquiring an additional 425,000 shares during the last quarter. Armistice Capital LLC boosted its position in shares of Corbus Pharmaceuticals by 179.2% during the 4th quarter. Armistice Capital LLC now owns 536,000 shares of the biopharmaceutical company’s stock worth $4,363,000 after purchasing an additional 344,000 shares during the period. Prosight Management LP boosted its position in shares of Corbus Pharmaceuticals by 99.1% during the 4th quarter. Prosight Management LP now owns 683,872 shares of the biopharmaceutical company’s stock worth $5,567,000 after purchasing an additional 340,472 shares during the period. Finally, ADAR1 Capital Management LLC increased its holdings in Corbus Pharmaceuticals by 2,711.6% in the 4th quarter. ADAR1 Capital Management LLC now owns 286,781 shares of the biopharmaceutical company’s stock valued at $2,334,000 after purchasing an additional 276,581 shares during the last quarter. Institutional investors and hedge funds own 64.64% of the company’s stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.